News >

Frontline Nivolumab/Ipilimumab Improves Response in mRCC

Jason Harris
Published: Wednesday, Aug 16, 2017

Vicki Goodman, MD

Vicki Goodman, MD
Topline results from the phase III CheckMate-214 trial showed that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved the objective response rate (ORR) and duration of response compared with sunitinib (Sutent) in patients with treatment-naïve metastatic renal cell carcinoma (RCC).

Single-agent nivolumab is currently approved by the FDA as a treatment for patients with metastatic RCC following prior antiangiogenic therapy.
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study [published online July 5, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.72.1985.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x